The favourable‐prognosis subgroup (Pattern 1) demonstrated significant enrichment of established oncogenic pathways, including MAPK and mTOR signalling cascades, consistent with the emerging paradigm of RiboSis‐mediated metabolic reprogramming in tumour progression. This evidence concerns the gene MTOR and neoplasm.